04 August 2026
04 August 2026
Completion of the deal is subject to shareholder and regulatory approvals and is anticipated by the end of the year.
The Phase III programme includes two trials enrolling 4,600 participants with obesity or overweight in the US, Canada, and Europe.
Of the 62 subjects, 30 had previously failed first-line venetoclax, where published remission rates are about 13%.
Located near Boston, the facility is intended to support assembly, inspection, testing, and manufacturing activities for the eShunt system.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
